» Articles » PMID: 36032075

Pan-cancer Analyses and Molecular Subtypes Based on the Cancer-associated Fibroblast Landscape and Tumor Microenvironment Infiltration Characterization Reveal Clinical Outcome and Immunotherapy Response in Epithelial Ovarian Cancer

Overview
Journal Front Immunol
Date 2022 Aug 29
PMID 36032075
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cancer-associated fibroblasts (CAFs) are essential components of the tumor microenvironment (TME). These cells play a supportive role throughout cancer progression. Their ability to modulate the immune system has also been noted. However, there has been limited investigation of CAFs in the TME of epithelial ovarian cancer (EOC).

Methods: We comprehensively evaluated the CAF landscape and its association with gene alterations, clinical features, prognostic value, and immune cell infiltration at the pan-cancer level using multi-omic data from The Cancer Genome Atlas (TCGA). The CAF contents were characterized by CAF scores based on the expression levels of seven CAF markers using the R package "GSVA." Next, we identified the molecular subtypes defined by CAF markers and constructed a CAF riskscore system using principal component analysis in the EOC cohort. The correlation between CAF riskscore and TME cell infiltration was investigated. The ability of the CAF riskscore to predict prognosis and immunotherapy response was also examined.

Results: CAF components were involved in multiple immune-related processes, including transforming growth factor (TGF)-β signaling, IL2-STAT signaling, inflammatory responses, and Interleukin (IL) 2-signal transducer and activator of transcription (STAT) signaling. Considering the positive correlation between CAF scores and macrophages, neutrophils, and mast cells, CAFs may exert immunosuppressive effects in both pan-cancer and ovarian cancer cohorts, which may explain accelerated tumor progression and poor outcomes. Notably, two distinct CAF molecular subtypes were defined in the EOC cohort. Low CAF riskscores were characterized by favorable overall survival (OS) and higher efficacy of immunotherapy. Furthermore, 24 key genes were identified in CAF subtypes. These genes were significantly upregulated in EOC and showed a strong correlation with CAF markers.

Conclusions: Identifying CAF subtypes provides insights into EOC heterogeneity. The CAF riskscore system can predict prognosis and select patients who may benefit from immunotherapy. The mechanism of interactions between key genes, CAF markers, and associated cancer-promoting effects needs to be further elucidated.

Citing Articles

Cancer-associated fibroblasts reveal aberrant DNA methylation across different types of cancer.

Schmidt M, Maie T, Cramer T, Costa I, Wagner W Clin Epigenetics. 2024; 16(1):164.

PMID: 39567960 PMC: 11580436. DOI: 10.1186/s13148-024-01783-y.


Reprogramming of normal fibroblasts into ovarian cancer-associated fibroblasts via non-vesicular paracrine signaling induces an activated fibroblast phenotype.

Axemaker H, Plesselova S, Calar K, Jorgensen M, Wollman J, de la Puente P Biochim Biophys Acta Mol Cell Res. 2024; 1871(7):119801.

PMID: 39038611 PMC: 11365755. DOI: 10.1016/j.bbamcr.2024.119801.


The β-arrestin1/endothelin axis bolsters ovarian fibroblast-dependent invadosome activity and cancer cell metastatic potential.

Rio D, Masi I, Caprara V, Ottavi F, Albertini Petroni G, Salvati E Cell Death Dis. 2024; 15(5):358.

PMID: 38777849 PMC: 11111729. DOI: 10.1038/s41419-024-06730-6.


Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway.

Licaj M, Mhaidly R, Kieffer Y, Croizer H, Bonneau C, Meng A Nat Commun. 2024; 15(1):1312.

PMID: 38346978 PMC: 10861537. DOI: 10.1038/s41467-024-45595-3.


Personalization of Therapy in High-Grade Serous Tubo-Ovarian Cancer-The Possibility or the Necessity?.

Wilczynski J, Paradowska E, Wilczynski M J Pers Med. 2024; 14(1).

PMID: 38248751 PMC: 10817599. DOI: 10.3390/jpm14010049.


References
1.
Jena B, Das C, Banerjee I, Das S, Bharadwaj D, Majumder R . Paracrine TGF-β1 from breast cancer contributes to chemoresistance in cancer associated fibroblasts via upregulation of the p44/42 MAPK signaling pathway. Biochem Pharmacol. 2021; 186:114474. DOI: 10.1016/j.bcp.2021.114474. View

2.
Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

3.
Givel A, Kieffer Y, Scholer-Dahirel A, Sirven P, Cardon M, Pelon F . miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. Nat Commun. 2018; 9(1):1056. PMC: 5849633. DOI: 10.1038/s41467-018-03348-z. View

4.
Sahai E, Astsaturov I, Cukierman E, DeNardo D, Egeblad M, Evans R . A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020; 20(3):174-186. PMC: 7046529. DOI: 10.1038/s41568-019-0238-1. View

5.
Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S . Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. Cancer Cell. 2017; 32(5):654-668.e5. PMC: 5827952. DOI: 10.1016/j.ccell.2017.10.005. View